PLOS Medicine: Using cfDNA to distinguish benign tumors from malignant tumors
Time of Update: 2021-09-12
Co-corresponding author Aadel Chaudhuri of the Settman Cancer Center of the University of Washington said: "Using the combination of ultra-low-depth whole-genome sequencing and free DNA fragment screening, we can specifically and sensitively distinguish MPNST patients from those with benign lesions.
New use of old medicine!
Time of Update: 2021-09-11
/>. >Bumetanide is a powerful diuretic that works by inhibiting the sodium-potassium-chloride cotransporter (NKCC1) . In February 1983, bumetanide
Hengrui Medicine's long-acting local anesthetic drug HR18034 for injection was approved for clinical use
Time of Update: 2021-08-29
analgesia-HR18034 for injection, in order to maintain the analgesic effect in patients for several days after surgery, thereby reducing the frequency of clinical administration, further reducing the risk of toxicity, and prolonging the effective
Hengrui Medicine HRS2300 tablets were approved for clinical use
Time of Update: 2021-08-28
Trial Approval Notice" for HRS 2300 tablets, and clinical trials will be launched in the near future . >>HRS2300 can inhibit the proliferation of tumor cells
Hengrui Medicine's HR19003 patch was approved for clinical use
Time of Update: 2021-08-15
On August 5, Hengrui Pharmaceuticals issued an announcement stating that the company has recently received the "Notice of Drug Clinical Trial Approval" for the HR19003 patch approved
Hengrui Medicine: HR17031 injection obtained the qualification of US FDA clinical trial
Time of Update: 2021-08-10
S. dollars, and the global sales of Soliqua 100/33 will be approximately 184 million U.
PLOS MED: Use medicine with caution!
Time of Update: 2021-08-04
Adjusted HR for out-of-hospital and total mortality of benzodiazepines and class Z drugs and trazodone based on concurrent opioid usePatients who use opioids at the same time currently use 4278 person-years, 90 people (21.
Hengrui Medicine SHR-1906 injection was approved for clinical use
Time of Update: 2021-08-02
has recently received the approval of the National Medical Products Administration to issue the "Drug Clinical Trial Approval Notice" for SHR-1906 injection, and clinical trials will be launched in the near future .
Renfu Medicine: Metoprolol Succinate Sustained-Release Tablets Obtained US FDA Approval Number
Time of Update: 2021-07-26
According to the website of the National Medical Products Administration, only AstraZeneca AB (hereinafter referred to as "AstraZeneca") obtained drug import registration for metoprolol succinate sustained-release tablets in China.
Jiangxi Nature, the first proprietary Chinese medicine company in the US stock market, closed down
Time of Update: 2021-07-14
According to the official website of the National Drug Administration, Jiangxi Nature Pharmaceutical has obtained multiple approval numbers for the production of medicines, including wind pain medicinal liquor, rheumatic pain medicinal liquor, Fuzilizhong pills, and axe-snake medicinal liquor .
Renfu Medicine HW021199 tablets are approved for clinical use in the treatment of idiopathic pulmonary fibrosis
Time of Update: 2021-07-07
On April 30, Renfu Medicine issued an announcement stating that recently, its subsidiary Hubei Biomedical Industry Technology Research Institute Co.
Heqirui Medicine completes US$56 million in Series B financing
Time of Update: 2021-07-07
According to the license agreement, Heqirui Medicine will develop and industrialize a new antibody targeting the prolactin (PRL) receptor globally based on Bayer's intellectual property rights .
Sihuan Medicine Degu Aspart Double Insulin Injection was approved for clinical use
Time of Update: 2021-07-06
On June 7, the official website of CDE showed that the diabetes drug Degu aspartic insulin injection developed by Jilin Huisheng Biological, a subsidiary of Sihuan Pharmaceutical, was approved for clinical use.
Tianyao Co., Ltd.: Subsidiary medicines have been approved by the US ANDA
Time of Update: 2021-07-06
On June 16, Tianyao Pharmaceutical announced that Jinyao Pharmaceutical, a subsidiary of the company, recently obtained the approval number of the new drug brief application (ANDA, US
Huadong Medicine: Sino-US Huadong Micafungin Sodium for Injection Approved for Listing
Time of Update: 2021-06-29
On June 18, Huadong Medicine announced that, recently, the company’s wholly-owned subsidiary Sino-American Huadong received the "Drug Registration Certificate" for Micafungin Sodium for Injection (50mg) approved and issued by the State Food and Drug Administration .
Mistletoe has a bright prospect for medicinal use, and the future market is bullish year by year!
Time of Update: 2021-06-22
>After entering the 21st century, with the continuous deepening of scientific research, the use of mistletoe has been expanded to varying degrees, the market share has increased day by day, and the demand has also shown an upward trend year by year
Gut: People with stomach problems, use this medicine with caution!
Time of Update: 2021-06-11
or not, or the PPI group that has received HP eradication treatment, they are further subdivided into 4 groups ≥30 days, ≥90 days, ≥180 days and ≥365 days according to the duration of medication. To investigate the dose-response relationship
How to use pharmaceutical equipment for the modernization of the Chinese medicine industry
Time of Update: 2021-06-08
> ] The Chinese medicine industry is an important part of the pharmaceutical industry, and it is also a strategic industry in China, which has a major bearing on the health of the national body. In recent years
Patients with lupus during pregnancy, don't use these medicines again!
Time of Update: 2021-06-01
The principles of medication for women with SLE during pregnancy include: stop any teratogenic drugs; pregnancy should be in a stable state and use the least drugs.
[First issue] Heqirui Medicine, dedicated to source innovation, successfully completed US$56
Time of Update: 2021-05-22
The Heqirui team led by Professor Xiao Ruiping has an international vision and experience, and is committed to the research and development of first-in-class innovative drugs based on an in-depth understanding of translational medicine.